Pleural mesothelioma

Pleural mesothelioma is a rare but aggressive cancer originating from the mesothelial cells lining the pleura, the membrane surrounding the lungs. One of the strongest contributors to disease development is long-term contact with asbestos fibers, which can gradually damage pleural tissue and trigger malignant changes over many years. Patients often report chest discomfort, persistent shortness of breath, fluid accumulation around the lungs, fatigue, and unexplained weight loss. Because early symptoms are subtle, diagnosis is frequently delayed. Radiologic evaluations such as chest X-rays, CT scans, and PET scans, together with pleural fluid examination and tissue biopsy, are crucial for confirming the diagnosis and determining the extent of the disease. Accurate staging informs prognosis and guides treatment decisions.

Management of pleural mesothelioma requires a multidisciplinary approach adapted to the patient’s disease stage, overall health, and goals of care. Surgical options like pleurectomy or extrapleural pneumonectomy may be considered for selected patients, while chemotherapy and radiation therapy help control tumor growth and alleviate symptoms. Newer therapies, including immunotherapy and targeted agents, are being explored to enhance survival and quality of life. Supportive care, encompassing pain management, respiratory therapy, and psychosocial support, is essential throughout treatment. Public health initiatives aimed at reducing asbestos exposure, along with early diagnosis and personalized therapeutic strategies, are central to improving outcomes for patients with pleural mesothelioma.